Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
Abstract Introduction The U.S. Food and Drug Administration (FDA)'s guidances help describe the agency's current thinking on regulatory issues and serve as a means of informal policymaking that is non‐binding. This study examines the impact of two guidance documents for Alzheimer's di...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142304587350016 |
|---|---|
| author | Jeffrey C. Yu Jakub P. Hlávka Elizabeth Joe Frances J. Richmond Darius N. Lakdawalla |
| author_facet | Jeffrey C. Yu Jakub P. Hlávka Elizabeth Joe Frances J. Richmond Darius N. Lakdawalla |
| author_sort | Jeffrey C. Yu |
| collection | DOAJ |
| description | Abstract Introduction The U.S. Food and Drug Administration (FDA)'s guidances help describe the agency's current thinking on regulatory issues and serve as a means of informal policymaking that is non‐binding. This study examines the impact of two guidance documents for Alzheimer's disease (AD) trials. The first guidance in 2013 encouraged the use of cognitive/functional endpoints, while the second in 2018 modified such recommendation. Methods Using pivotal trial data, we applied a regression discontinuity in time (RDiT) framework to examine trialist response to these guidance documents. Results were stratified by disease‐modifying therapy (DMT) status, and controlled for disease staging, FDA registration status, and trial phase. Results Among AD DMT trials, annual use of cognitive/functional composite endpoints significantly increased after the 2013 guidance (+12.9%, P < .001), and significantly decreased after the 2018 guidance (–19.9%, P = .022). Discussion Although guidance documents do not set new legal standards or impose binding requirements, our findings indicate they are broadly followed by AD trialists. |
| format | Article |
| id | doaj-art-ccfa05ce0c8e46e28a0c63e0fded3f22 |
| institution | Kabale University |
| issn | 2352-8737 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-ccfa05ce0c8e46e28a0c63e0fded3f222024-12-03T12:37:31ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12280Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trialsJeffrey C. Yu0Jakub P. Hlávka1Elizabeth Joe2Frances J. Richmond3Darius N. Lakdawalla4School of Pharmacy University of Southern California Los Angeles California USALeonard D. Schaeffer Center for Health Policy & Economics Los Angeles California USAKeck School of Medicine University of Southern California Los Angeles California USASchool of Pharmacy University of Southern California Los Angeles California USASchool of Pharmacy University of Southern California Los Angeles California USAAbstract Introduction The U.S. Food and Drug Administration (FDA)'s guidances help describe the agency's current thinking on regulatory issues and serve as a means of informal policymaking that is non‐binding. This study examines the impact of two guidance documents for Alzheimer's disease (AD) trials. The first guidance in 2013 encouraged the use of cognitive/functional endpoints, while the second in 2018 modified such recommendation. Methods Using pivotal trial data, we applied a regression discontinuity in time (RDiT) framework to examine trialist response to these guidance documents. Results were stratified by disease‐modifying therapy (DMT) status, and controlled for disease staging, FDA registration status, and trial phase. Results Among AD DMT trials, annual use of cognitive/functional composite endpoints significantly increased after the 2013 guidance (+12.9%, P < .001), and significantly decreased after the 2018 guidance (–19.9%, P = .022). Discussion Although guidance documents do not set new legal standards or impose binding requirements, our findings indicate they are broadly followed by AD trialists.https://doi.org/10.1002/trc2.12280Alzheimer's diseaseClinical Dementia Rating Sum of Boxesclinical trialscomposite endpointsFood and Drug Administrationguidance documents |
| spellingShingle | Jeffrey C. Yu Jakub P. Hlávka Elizabeth Joe Frances J. Richmond Darius N. Lakdawalla Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials Alzheimer’s & Dementia: Translational Research & Clinical Interventions Alzheimer's disease Clinical Dementia Rating Sum of Boxes clinical trials composite endpoints Food and Drug Administration guidance documents |
| title | Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials |
| title_full | Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials |
| title_fullStr | Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials |
| title_full_unstemmed | Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials |
| title_short | Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials |
| title_sort | impact of non binding fda guidances on primary endpoint selection in alzheimer s disease trials |
| topic | Alzheimer's disease Clinical Dementia Rating Sum of Boxes clinical trials composite endpoints Food and Drug Administration guidance documents |
| url | https://doi.org/10.1002/trc2.12280 |
| work_keys_str_mv | AT jeffreycyu impactofnonbindingfdaguidancesonprimaryendpointselectioninalzheimersdiseasetrials AT jakubphlavka impactofnonbindingfdaguidancesonprimaryendpointselectioninalzheimersdiseasetrials AT elizabethjoe impactofnonbindingfdaguidancesonprimaryendpointselectioninalzheimersdiseasetrials AT francesjrichmond impactofnonbindingfdaguidancesonprimaryendpointselectioninalzheimersdiseasetrials AT dariusnlakdawalla impactofnonbindingfdaguidancesonprimaryendpointselectioninalzheimersdiseasetrials |